Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the use of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL). Dr Woyach highlights how the treatment used impacts the prognostic nature of MRD status. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.